LUPKYNIS Will Continue to Be Refined for Improved Lupus Nephritis Treatment
Aurinia Pharmaceuticals, Inc. announced its medication LUPKYNIS® (voclosporin) may soon be used in new and improved ways for the treatment of lupus nephritis (LN, lupus-related kidney disease). The United States Patent and Trademark Office has opened a method-of-use patent application titled, “Improved Protocol for the Treatment of Lupus Nephritis,” which will allow for the development of new and refined ways of using the therapy in people with active LN in combination with other treatments.
The latest news marks an exciting step in the advancement of LN therapy. Approved by the U.S. Food and Drug Administration (FDA) in 2021, LUPKYNIS is the first FDA-approved oral medication for the treatment of adults with active LN, a serious disease affecting up to 60% of people with lupus.
Continue to follow the Lupus Foundation of America for breaking news in lupus drug development, and learn more about LUPKYNIS.
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.Subscribe Now